Clinical Efficacy of Gujian Powder Combined with Shockwave in the Treatment of Early Osteonecrosis of the Femoral Head

Objective: To observe the clinical efficacy of Gujiansan combined with extracorporeal shockwave therapy for early osteonecrosis of the femoral head (ONFH). Methods: Sixty patients with early ONFH were selected and randomly divided into three groups, with 20 cases in each group. The experimental group was treated with oral Gujiansan combined with extracorporeal shockwave therapy. Control group A was treated with Gujiansan orally, while control group B was treated with Xianling Gubao capsules orally. Result: Compared with before treatment, the VAS score, Harris score, and bone density of the experimental group and control groups A and B were significantly improved at 30, 90, and 180 days after treatment, with statistically significant differences. Compared with the control groups A and B, the experimental group showed more significant improvements in VAS score, Harris score, and bone density at 30, 90, and 180 days after treatment, with statistically significant differences. Conclusion: The combination of Gujiansan and extracorporeal shockwave therapy significantly improves VAS score, Harris score, and bone density in patients with early osteonecrosis of the femoral head, effectively reduces pain, and improves patient quality of life. Thus, it is worth promoting in the clinics.